Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) filed its Monthly Return for the period ended 30 April 2026, showing no changes in share capital structure.

Authorised and Issued Share Capital • Authorised/registered capital and issued shares both closed the month unchanged at 170.55 million ordinary H-shares with a par value of RMB1.00 each, equal to RMB170.55 million in registered share capital. • No treasury shares were held or cancelled during the period.

Public Float Status • The company reconfirmed compliance with the Hong Kong Main Board’s minimum public float requirement. The threshold set at listing was 15.61 % of issued H-shares (excluding treasury shares).

Equity Incentives • 2.11 million share options remain outstanding under the Pre-IPO Share Option Scheme, carrying an exercise price of RMB3.70 per share. • No options vested or were exercised in April; the earliest vesting date is 9 January 2028.

Other Capital Movements • The issuer reported no warrants, convertibles, additional option arrangements, or other share movements for the month.

Governance Confirmation • The submission was signed by Joint Company Secretary Mr. Zhang Su, affirming adherence to all applicable listing rules and regulatory requirements.